康臣药业(01681.HK)SK-08片剂首批受试者成功用药

阿斯达克财经
13 Mar

康臣药业(01681.HK) 公布,集团正在进行评估SK-08片剂的安全性、耐受性及药代动力学特征的临床一期试验,首批受试者已成功用药。在临床前试验中,SK-08片剂显著降低尿蛋白、改善肾脏功能与肾小球硬化,安全性耐受性良好。(de/d)(港股报价延迟最少十五分钟。沽空资料截至 2025-03-13 16:25。)

AASTOCKS新闻

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10